Filana Therapeutics (FLNA) Total Current Liabilities (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Total Current Liabilities of $40.2 million for Q2 2026, down 15.16% year-over-year from $47.3 million in Q2 2025, and little changed quarter-over-quarter from $40.1 million in Q1 2026.
Filana Therapeutics (FLNA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Filana Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $40.2 million for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 15.16% year-over-year to $40.2 million; the TTM figure through Jun 2026 stood at $40.2 million (down 15.16% YoY), while the FY2025 annual figure was $43.8 million, up 273.06% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $40.2 million, roughly flat from $40.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $77.1 million in Q1 2024, with the low at $6.8 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $17.7 million (2023), against an average of $29.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 454.47% in 2024, then tumbled 82.84% in 2025.
- Filana Therapeutics' Total Current Liabilities stood at $7.1 million in 2022, then surged by 100.98% to $14.2 million in 2023, then retreated by 17.22% to $11.8 million in 2024, then surged by 273.06% to $43.8 million in 2025, then decreased by 8.39% to $40.2 million in 2026.
- Business Quant data shows FLNA's Total Current Liabilities at $40.2 million in Q2 2026, $40.1 million in Q1 2026, and $43.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - | 40.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.16 Mn |
| Mar 31, 2026 | 40.12 Mn |
| Dec 31, 2025 | 43.83 Mn |
| Sep 30, 2025 | 48.05 Mn |
| Jun 30, 2025 | 47.33 Mn |
| Mar 31, 2025 | 13.24 Mn |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 57.03 Mn |
| Jun 30, 2024 | 54.59 Mn |
| Mar 31, 2024 | 77.12 Mn |
| Dec 31, 2023 | 14.20 Mn |
| Sep 30, 2023 | 17.41 Mn |
| Jun 30, 2023 | 17.90 Mn |
| Mar 31, 2023 | 13.91 Mn |
| Dec 31, 2022 | 7.06 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 8.72 Mn |
| Mar 31, 2022 | 6.79 Mn |
| Dec 31, 2021 | 12.53 Mn |
| Sep 30, 2021 | 6.33 Mn |